Harvard Law School on Wednesday announced the launch of a first-of-its-kind psychedelics policy center that it hopes will inform legislation and help clinicians navigate this burgeoning medical space as reform continues to advance.
Psychedelics
The Mental Health Pandemic Soars Into Focus, Psychedelics In The Spotlight
As the Mental Health Pandemic spirals out of control, we see a positive sign: the mainstream media has finally noticed it.
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression
Compass Pathways completes the world's largest psilocybin-based clinical trial as the 216th patient in its trial completed their treatment.
Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement
In pre-clinical testing, multiple proprietary molecules "showed consistent positive results when compared to the parent molecule".
Cybin Inc. Releases Annual Financials and Provides Business Highlights
Cybin Inc releases its full-year financial results for the fiscal year ended March 31, 2021 and provides business highlights.
MindMed Included in FTSE Russell 3000® Index
MindMed officially announces its inclusion in the FTSE Russell 3000.
Psyched Wellness Commences Next Pre-Clinical Study on AME-1
Psyched Wellness announces its latest pre-clinical study on AME-1.
Use of mescaline may facilitate unintended improvements in several psychiatric conditions, study suggests
The use of mescaline, a psychedelic substance derived from the peyote cactus, appears to be associated with improvements in depression and anxiety, according to a new preliminary study published in the journal ACS Pharmacology & Translational Science.
Psychedelic Medicine: Will The High Always Be Part Of The Therapy?
Psychedelic Stock Watch explains why astute investors will put their dollars into both "experiential" and non-psychoactive psychedelic drug R&D.
Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results
Field Trip reports Q4 and full-year results for fiscal 2021. Cash position of CAD$111m. Clinic revenues increased by 63% q-o-q to CAD$526,435.
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
Mydecine's novel molecule, MYCO-004 is targeting multiple forms of addiction/substance abuse.
Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species
Numinus files a patent application for a "process" that can allow faster, more cost-effective production of psychoactive compounds such as psilocybin.
Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board
The newest member of Cybin's Clinical Advisory Board previously held a senior position with the FDA.
Alternatives to ATAI: Go Big Or Go Small?
Sometimes biggest is not "best". Psychedelic Stock Watch offers investors a lot of reasons why thinking SMALLER may be more profitable.
Novamind Welcomes Dr. Paul Thielking as Chief Scientific Officer
Novamind's new Chief Scientific Officer is a physician with deep knowledge of psychiatry and palliative care, including familiarity with ketamine-assisted psychotherapy.